Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Bio-Rad Laboratories

Explore full profile

Bio-Rad | Products for Life Science Research & Clinical Diagnostics

Hercules, United StatesFounded 1952Biotech & Life Sciences
Valuation $10B Market cap · 2026
Revenue $2.57B Latest reported FY
EBITDA $396M Latest reported FY

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc. is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostics markets. The company serves academic institutions, pharmaceutical companies, biotechnology firms, and clinical laboratories. Bio-Rad operates in the highly competitive life sciences and diagnostics markets, offering products that include reagents, instruments, and software for cell biology, gene expression, protein purification, and imaging. The business model focuses on selling these products directly to customers through a dedicated sales force and online platforms, generating revenue through product sales and service contracts. Bio-Rad's commitment to quality and innovation helps researchers and clinicians advance their discoveries and improve patient outcomes.

Source: Dealroom company data

At a glance

Status
Listed
Founded
1952
Headquarters
Hercules, United States
Listing
IPO 1980
Employees
9,410
Open positions
113
Dealroom signal
36.2/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Diabetes, Biotechnology, DNA, Genetics and genomics, observatoire healthtech
Business model
Manufacturing
Client focus
b2b
Investment activity
13 companies, latest Feb 2026
Capital deployed
$123M
Preferred round
ACQUISITION

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
POST IPO DEBT✓Debt Feb 2024 $200M — Citibank · JP Morgan · Wells Fargo Securities ↗
POST IPO DEBT✓Debt Mar 2022 $1.2B — Undisclosed ↗
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

YearRevenueGrowthEBITDAMarginProfitMarginR&D
2026 $2.6B -0.5% $396M 15.4% $225M 8.8% $276M
2025 $2.6B +0.7% $481M 18.6% $760M 29.4% $276M
2024 $2.6B -3.9% $504M 19.6% −$1.8B -71.9% $296M
2023 $2.7B -4.7% $587M 22% $247M
2022 $2.8B -4.1% $664M 23.7%
2021 $2.9B +14.8% $650M 22.2%
2020 $2.5B — $574M 22.5%
Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Bio-Rad Laboratories website traffic

Latest recorded traffic for Bio-Rad Laboratories is 690K monthly website visits, up 30.2% over the last three months. Bio-Rad Laboratories's team grew 4.8% over the past year.

Latest monthly visits690K 3-month web change+30.2% 1-year team growth+4.8%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Oncocyte CorporationNashville, United StatesPrecision diagnostics for oncology and transplant monitoring AfyniaHamilton, CanadaEndometriosis tests $20Mvaluation Stilla TechnologiesVillejuif, FranceBiotechnology company that focuses on accelerating the development of next-generation genetic tests $225Mvaluation OncoCyteNashville, United StatesFocused on cancers with large patient populations and significant unmet need $113Mvaluation GeneoscopyMaryland Heights, United StatesGeneoscopy is developing a screening methodology to noninvasively diagnose colorectal cancer using biomarkers in stool samples $420Mvaluation Curiosity Diagnostics Sp z.o.o.Warsaw, PolandPCR One – Help when you need it most Celsee DiagnosticsPlymouth, United StatesInnovative single-cell analysis solutions for advancing life sciences research and diagnostics $32Mvaluation Osler DiagnosticsOxford, United KingdomA ground-breaking handheld diagnostic for testing a vast range of biomarkers $392Mvaluation GnuBIOCambridge, United StatesDeveloper of scalable dna sequencing technology for the diagnostic and applied markets $50Mvaluation AbD SerotecRaleigh, United StatesA world leading antibody manufacturer supplying antibodies, kits and accessories $58Mvaluation QuantaLifePleasanton, United StatesProducts and services for the life science research and clinical diagnostic markets $162Mvaluation DiaMed Holding AGCressier, SwitzerlandImmunohematology, Infectious Disease Testing, QC, Microbiology, Diabetes & Autoimmune Testing $393Mvaluation

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later3 investors entered at this stage

  • JP Morgan
  • Citibank
  • Wells Fargo Securities
Team profiled 152 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Hercules HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Bio-Rad Laboratories on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Bio-Rad Laboratories’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.